Navigation Links
Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
Date:3/31/2009

ANNAPOLIS, Md., March 31 /PRNewswire-FirstCall/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new mechanism of action data for Valortim(R) were presented at the Keystone Symposia on Molecular and Cellular Biology Conference on Dendritic Cells, March 29-April 3, 2009 in Banff, Alberta.

The data were presented by Dr. Alan S. Cross, Professor of Medicine and Dr. Subhendu Basu, Research Associate, University of Maryland School of Medicine, in a poster presentation on March 30th entitled MAb-Enhanced, Human Dendritic Cell-Mediated Adaptive Immune Response to B. Anthracis. Valortim(R) is a fully human anti-toxin monoclonal antibody being developed in conjunction with Medarex, Inc. for the prevention and treatment of inhalational anthrax.

Previous mechanism of action data have shown that in addition to inhibiting anthrax toxin, Valortim(R) augments the immune system's ability to kill anthrax bacilli. In an in vitro mouse macrophage model, Valortim(R) enhanced the killing of B. anthracis (anthrax) by macrophages in a time and dose-dependent manner.

The new data presented by Drs. Cross and Basu build on this initial information in the mouse model by demonstrating that Valortim(R) can enhance the killing of anthrax by human dendritic cells.

Dr. Cross remarked, "These latest studies using human immune cells provide additional evidence of the role of Valortim(R) in enhancing the killing of B. anthracis. We hypothesize that Valortim(R) may protect against lethal anthrax infection by its toxin neutralization activity that allows the development of a potent human dendritic cell-mediated adaptive response that rids the host of viable bacteria."

D
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 29 Asahi Kasei Medical Co., Ltd. is pleased to ... MF-SL, its new range of microfilters for bioprocessing applications. Designed specifically ... biopharmaceutical manufacturers to improve the efficiency and effectiveness of their protein ... , ...
... IRIDEX Corporation (Nasdaq: IRIX ) today announced that it will release its ... August 5, 2010 .  In conjunction with the release, the Company will ... Eastern Time on Thursday, August 5, 2010 ... , , ...
Cached Medicine Technology:Launch of BioOptimalâ„¢ MF-SL Microfilters for Bioprocessing 2IRIDEX Announces Second Quarter 2010 Conference Call and Release Date 2
(Date:4/18/2014)... University School of Medicine researchers have been awarded two-year ... Novo Nordisk announced this month. Of the 110 initial ... Biologics Science Forum Program, only four projects were funded, ... They are Jonathan Powell, M.D., Ph.D.; G. William Wong, ... Powell, a professor of oncology, will use his $500,000 ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... bog outshines 19 commonly eaten fruits for the ... latest,Agricultural Research Service Report from USDA, containing the ... foods, shows cranberries,score among the highest of all ... The report includes antioxidant values for a ...
... Children with autism have normal-size heads at birth but ... of age, a period that precedes the onset of ... disorder, according to new research from the University of ... aberrant growth is present in children who have the ...
... Conn.A protein has been found that influences the response of ... such as occurs during a heart attack, a team of ... This finding may present a new therapeutic approach to treating ... The protein, macrophage migration inhibitory factor (MIF), was found to ...
... Bay Park to be the focus of this inaugural ... ... An unclimbed mountain near Mount Abbe,in the northern reaches of Alaska,s ... Expedition for Cancer Research, a quest,sponsored by Fred Hutchinson Cancer Research ...
... 30 Prime Therapeutics (Prime) has,joined the Center ... from,the pharmacy benefit manager (PBM) industry. The Center ... collaborates with leading,organizations to develop and promote innovative ... the health of employees. Members,of the Center represent ...
... estrogen 55 times faster , , WEDNESDAY, Jan. 30 (HealthDay ... release a potentially harmful chemical 55 times faster than ... found in the plastics that make up water bottles, ... acts as an environmental estrogen and can disrupt the ...
Cached Medicine News:Health News:Cranberries' Antioxidant Level Tops List in USDA Report 2Health News:Cranberries' Antioxidant Level Tops List in USDA Report 3Health News:Accelerated head growth can predict autism before behavioral symptoms start 2Health News:Hutchinson Center Announces First Unclimbed Mountain to be Tackled by Big Expedition for Cancer Research 2Health News:Prime Therapeutics Becomes First PBM to Join the Center for Health Value Innovation 2Health News:Heating Plastic Bottles Releases Potentially Harmful Chemical 2Health News:Heating Plastic Bottles Releases Potentially Harmful Chemical 3
... is an automated, multiparametric immunoassay ... device stores the calibration in ... the cost-per-patient result. Plus, with ... ease of use and uni/bi-directional ...
Alpha prime immunoassay system features unsurpassed quality of results, full automation of EIA tests for microplate applications, complete walk-away, up to 18 different assays per run, photometric an...
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: